Tarsus Pharmaceuticals Stock Current Valuation
| TARS Stock | USD 48.24 1.84 3.97% |
Valuation analysis of Tarsus Pharmaceuticals helps investors to measure Tarsus Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 635.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.20) in 2024. Fundamental drivers impacting Tarsus Pharmaceuticals' valuation include:
Price Book 7.765 | Enterprise Value 1.6 B | Enterprise Value Ebitda (3.23) | Price Sales 14.2266 | Enterprise Value Revenue 12.3395 |
Fairly Valued
Today
Please note that Tarsus Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Tarsus Pharmaceuticals is based on 3 months time horizon. Increasing Tarsus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tarsus stock is determined by what a typical buyer is willing to pay for full or partial control of Tarsus Pharmaceuticals. Since Tarsus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tarsus Stock. However, Tarsus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.24 | Real 48.47 | Target 46.0 | Hype 48.85 | Naive 45.97 |
The intrinsic value of Tarsus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tarsus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tarsus Pharmaceuticals helps investors to forecast how Tarsus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tarsus Pharmaceuticals more accurately as focusing exclusively on Tarsus Pharmaceuticals' fundamentals will not take into account other important factors: Tarsus Pharmaceuticals Company Current Valuation Analysis
Tarsus Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tarsus Pharmaceuticals Current Valuation | 1.6 B |
Most of Tarsus Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tarsus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tarsus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Tarsus Pharmaceuticals is extremely important. It helps to project a fair market value of Tarsus Stock properly, considering its historical fundamentals such as Current Valuation. Since Tarsus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tarsus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tarsus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Tarsus Current Valuation Historical Pattern
Today, most investors in Tarsus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tarsus Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tarsus Pharmaceuticals current valuation as a starting point in their analysis.
Tarsus Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Tarsus Pharmaceuticals has a Current Valuation of 1.6 B. This is 88.86% lower than that of the Pharmaceuticals sector and 65.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 90.38% higher than that of the company.
Tarsus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics of similar companies.Tarsus Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Tarsus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tarsus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tarsus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Tarsus Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 38.23 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 91.30 % | ||||
| Number Of Shares Shorted | 8.16 M | ||||
| Price To Book | 7.76 X | ||||
| Price To Sales | 14.23 X | ||||
| Revenue | 17.45 M | ||||
| Gross Profit | (17.76 M) | ||||
| EBITDA | (131.67 M) | ||||
| Net Income | (135.89 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 31.73 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 6.22 X | ||||
| Cash Flow From Operations | (117.49 M) | ||||
| Short Ratio | 11.42 X | ||||
| Earnings Per Share | (3.75) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 65.33 | ||||
| Number Of Employees | 244 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 1.84 B | ||||
| Total Asset | 265.49 M | ||||
| Retained Earnings | (244.66 M) | ||||
| Working Capital | 219.19 M | ||||
| Net Asset | 265.49 M |
About Tarsus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.